開發探針修飾磁性奈米矽球並輔以非酵素型核酸分子催化放大訊號技術之光學感測平台來檢測心血管疾病因子

Synthesis of probe-modified silica-coated magnetic beads in combination of non-enzymatic catalytic amplification reaction to develop an optical sensing platform for the detection of cardiovascular disease

吳書任(SHU-REN WU)

指導教授 ： 周芳如

中原大學/理學院/化學研究所/碩士(2020年)

https://doi.org/10.6840/cycu202000719

摘要

根據報導統計心血管疾病 (Cardiovascular diseases, CVD)佔全球總死亡人數的 31%，並且逐年的攀升且年輕化，是目前第一大的死亡原因，然而心血管疾病若能提早受到診斷並接受藥物治療是有助於患者提高存活率。因此，本研究在開發用於診斷 CVD 的生物感測平台。許多研究證實 miR-208a 與 CVD 有相當大的關聯，並且作為 CVD 的潛在標記。透過 DNA 探針官能化修飾及易於分離的磁性奈米粒子建構了非酵素型光學生物感測平台。我們準備了不同修飾方法的磁性奈米粒子，並研究出最佳化的修飾條件，來作為 DNA 探針的模板，再透過富含鳥嘌呤 (Guanine)的產物來催化四甲基聯苯胺 (Tetramethyl benzidine TMB)，並利用此氧化還原反應所得的比色訊號來分析目標 miR208a。透過訊號差異能使我們區分目標 miR-208a 是否存在。然而，此感測平台還需要改善對低濃度檢測的靈敏度。

關鍵字

心血管疾病 (CVD) ； 生物感測器 ； miRNA ； 光學

並列摘要

According to the reports, cardiovascular diseases (CVD) accounts for 31% of the global death, and the number is not only rising, but also the patient age is decreasing. With early detection and proper treatment, the survival rate can be greatly improved. In response, this thesis aims to develop a biosensing platform for diagnosing CVD. MiR-208a, found to be associated with CVD, is selected as the potential target. A enzyme-free optical biosensing platform is constructed based on DNA probe-functionalized, easy-separable magnetic particles. We prepare different modified-magentic particles to study the optimal carrier to maximize the efficient loading of DNA probes, take advantage of guanine-rich-containing products to catalyze the oxidation of tetramethyl benzidine (TMB), and avail the resulting colorimetric signal for the analysis of the target miR-208a. For the time being, the signal difference allows us to distinguish the presence of target miR-208a; however, improvements still need for lowconcentration detection.

並列關鍵字

cardiovascular diseases ； CVD ； biosensing ； miRNA ； optical

參考文獻

1. Luepker, R. V., Cardiovascular disease: rise, fall, and future prospects. Annu Rev Public Health 2011, 32, 1-3.

2. Arnett, D. K.; Blumenthal, R. S.; Albert, M. A.; Buroker, A. B.; Goldberger, Z. D.; Hahn, E. J.; Himmelfarb, C. D.; Khera, A.; Lloyd-Jones, D.; McEvoy, J. W.; Michos, E. D.; Miedema, M. D.; Munoz, D.; Smith, S. C., Jr.; Virani, S. S.; Williams, K. A., Sr.; Yeboah, J.; Ziaeian, B., 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 140 (11), 596-646.

3. Mortality, G. B. D.; Causes of Death, C., Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385 (9963), 117-71.

4. Newburger, J. W.; Takahashi, M.; Gerber, M. A.; Gewitz, M. H.; Tani, L. Y.; Burns, J. C.; Shulman, S. T.; Bolger, A. F.; Ferrieri, P.; Baltimore, R. S.; Wilson, W. R.; Baddour, L. M.; Levison, M. E.; Pallasch, T. J.; Falace, D. A.; Taubert, K. A.; Committee on Rheumatic Fever, E.; Kawasaki Disease, C. o. C. D. i. t. Y. A. H. A., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114 (6), 1708-33.

5. Zuliani, V.; Rivara, M.; Fantini, M.; Costantino, G., Sodium channel blockers for neuropathic pain. Expert Opin Ther Pat 2010, 20 (6), 755-79.